Skip to main content

Share story

AI

OpenAI model deprecations on March 26, 2026

OpenAI will deprecate several models on March 26, 2026. The following models will no longer be available for selection starting March 26, 2026. They are gpt 4 0314, gpt 4 1106 preview, gpt 4 0125 preview, gpt 4 turbo preview and gpt 4 turbo preview completions. Users will no longer be able to use these models in their scenarios. Scenarios using these models will continue to run without interruption when this happens. Requests will automatically be processed by gpt 4 1. No action is required on your part. Your scenarios will continue to run without interruption after the models are deprecated. Existing scenarios that use deprecated models might still display the model name in the model dropdown. They will use gpt 4 1 for future requests. Outputs may vary slightly due to differences in model behavior. For more information about using openai modules in make, see the openai app documentation at https //apps make com/openai gpt 3.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Make and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.